card-3216_Biochemistry expert scientific with eyeglasses
Digital innovation

Driving operational improvements and quality of our services

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3242_Scientist using tablet while colleagues working behind
Download our Corporate brochure

We are IQVIA Laboratories, a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions.

Download
card-3233_Laboratory scientist working at lab with micropipette, and 96 well plate
Corporate Video

Our commitment to customer success is embedded in every facet of our operations.

Learn more
card-3210_Laboratory technicians conduct a series of tests on a chemical analyzer
Science Innovation

Uniquely positioned to shape, validate, and deliver biomarker assessments that strive to improve patient outcomes across diverse Therapeutic Areas

Learn more
card-3216_Biochemistry expert scientific with eyeglasses
Digital Innovation

Driving operational improvements and quality of our services

Learn more
English You are about to exit for another IQVIA country or region specific website Please be aware that the website you have requested is intended for the residents of a particular country or region, as noted on that site. Ok Open in new tab Search

Insight

Tumor Mutational Burden (TMB) analysis across multiple genomic platforms with considerations for sample type utility and effects on numerical representation

Why Tumor Mutational Burden (TMB)?
Home / Insights / Tumor Mutational Burden (TMB) analysis across multiple genomic platforms with considerations for sample type utility and effects on numerical representation

Authors: Victor Weigman, Ph.D. and Stephanie Hastings, Ph.D.

In this presentation, you will learn about the impact of various molecular endpoints for facilitating therapeutic selection with considerations to the
patient’s immune response.   Determining the tumor mutational burden (TMB) has increased in adoption as a biomarker but how it is determined and the implications on interpretation are not standardized. We outline conventions for TMB calculation and suggest algorithm approaches and effects across matched samples tested with Exome, targeted panels, independent of normal samples.  Using colorectal cancer specimens, we demonstrate utility for extending traditional biomarker testing of FFPE into liquid biopsy inclusive of TMB calculation. We also review updates enhancing algorithms calling TMB with tumor tissue only, showing high linearity concordance to paired calls with high reproducibility and RNA-Sequencing, which are novel frontiers in this space and can extend advantage of TMB in datasets and specimens.